Shocking Revelations in Diabetes Treatment: Does Metformin Really Fall Short for Type 1 Diabetes?
Picture this: a widely used drug that's hailed as a game-changer for managing type 2 diabetes, yet when it comes to type 1 diabetes, it might not be the hero we thought. But here's where it gets controversial—could this challenge everything we know about repurposing medications across diabetes types? Let's dive into the latest findings from the INTIMET study and explore why this matters for patients and doctors alike.
Exciting news (or perhaps puzzling news) comes from the INTIMET study, which revealed no notable distinctions between metformin and a placebo when it came to addressing insulin resistance in the liver, muscles, or fat tissues. For beginners wondering what insulin resistance means, think of it as the body's cells becoming less responsive to insulin, the hormone that helps regulate blood sugar. In type 1 diabetes (T1D), where the immune system attacks insulin-producing cells, this resistance can make blood sugar management even trickier, potentially leading to complications like heart issues.
To break it down, metformin—a budget-friendly and generally safe pill often prescribed first for type 2 diabetes (T2D)—didn't show any enhancements in insulin sensitivity for these key tissues after 26 weeks of treatment in adults with T1D. This insight stems from the Insulin in Type 1 Diabetes Managed with Metformin (INTIMET) trial, published in Nature Communications. Backing this up, metformin excels in T2D by tweaking how glucose is processed in muscles and the liver, as confirmed by advanced tests like the hyperinsulinemic-euglycemic clamp. Imagine this test as a controlled experiment where doctors infuse insulin and glucose to measure how well the body handles it—it's like a high-tech way to check engine efficiency in a car. Plus, reviews of various trials suggest metformin can lower the total daily insulin needed in T1D, which some experts see as a sign of better insulin sensitivity. But here's the part most people miss: those clamp studies in T1D have mostly targeted teens, leaving a big gap in adult research.
As Jennifer Snaith, MBBS, B. Med. Sci, an endocrinologist and researcher at the Garvan Institute of Medical Research, along with her team, pointed out, 'However, studies in type 1 diabetes using the gold-standard clamp technique to directly measure insulin resistance have only been performed in adolescents. No study has employed the clamp technique to assess the effect of metformin on insulin resistance in adults with type 1 diabetes.'
The INTIMET project kicked off as a broad look at insulin resistance in adults with and without T1D, measuring it in muscles, liver, and fat via biochemical markers and health metrics. It then evolved into a 6-month randomized, controlled trial to investigate if adding metformin to insulin therapy could lower liver insulin resistance in T1D patients compared to placebo, boosting heart-related health markers without extra side effects. For instance, think of it like testing if a supplement can make your car's fuel system more efficient without causing breakdowns.
Who could join? Adults aged 20-55 with T1D lasting at least 10 years, very low fasting C-peptide (a sign of little remaining insulin production), and an HbA1c under 9.5% (that's about 80 mmol/mol, a measure of average blood sugar over time). They excluded anyone on meds or with conditions that might mess with insulin sensitivity, like certain thyroid issues. Insulin resistance was evaluated using the sophisticated 3-stage hyperinsulinemic-euglycemic clamp with labeled glucose tracers. The main goal? Track changes in endogenous glucose production (EGP), which is how much glucose the liver makes on its own during the low-insulin phase of the test.
They recruited 40 people total: 20 with T1D and 20 without. Everyone got a full health check between November 2019 and December 2021. For the T1D group, average age was 37.4 years (plus or minus 8.8), T1D had been around for about 22.9 years (give or take 8.9), BMI hovered at 26.3 kg/m² (plus or minus 3.8), daily insulin dose was 0.6 units per kg of body weight, and HbA1c averaged 7.5% (plus or minus 0.9%). The non-T1D controls were similar in age (37 ± 8.4 years) and BMI (26.2 ± 4.3), but their HbA1c was lower at 5.1% (plus or minus 0.3%).
Interestingly, the T1D participants showed more insulin resistance in liver, fat, and muscle compared to controls, with higher EGP rates (5.9 ± 2.2 µmol/kg fat-free mass/min vs. 3.6 ± 1.7 for controls; P = .0002) and elevated non-esterified fatty acids (NEFA) during low insulin (0.08 ± 0.01 mmol/L vs. 0.02 ± 0.02; P = .001). This points to trouble in shutting down liver glucose output and fat breakdown under insulin's influence—key issues in T1D that can lead to unstable blood sugar.
In the end, 37 out of 40 finished the study. After 26 weeks, there was no meaningful change in EGP between metformin and placebo groups (difference of 0.2 µmol/kg fat-free mass/min; 95% CI, -0.4 to 0.8; P = .53). No uptick in low blood sugar episodes or diabetic ketoacidosis either—always a relief in diabetes research.
Snaith and her colleagues concluded, 'These results do not support prescribing metformin to reduce insulin resistance in adults with type 1 diabetes but suggest that metformin may reduce insulin dose via mechanisms independent of insulin resistance. The potential cardiovascular benefits of insulin sparing and reducing peripheral hyperinsulinemia warrant further study.'
But here's where it gets really controversial: While the study says metformin doesn't tackle insulin resistance directly in T1D, some might argue that its insulin-saving effects could still offer hidden perks, like protecting the heart by cutting down on excess insulin circulating in the body. Is this a missed opportunity, or does it open doors for new research? What do you think—should we still consider metformin for T1D off-label, or does this prove it's not worth it? Share your views in the comments below; I'd love to hear if you agree, disagree, or have your own experiences with diabetes treatments!
References
Snaith JR, Olsen N, Evans J, et al. Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial. Nat Commun. 2025;16(1):9884. Published 2025 Nov 24. doi:10.1038/s41467-025-65951-1 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12644478/)
Liu YS, Chen CN, Chen ZG, Peng Y, Lin XP, Xu LL. Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2020;36(6):e3334. doi:10.1002/dmrr.3334 (https://pubmed.ncbi.nlm.nih.gov/32390336/)
Newsletter
Want to stay ahead of the curve with the latest on treatments, studies, and expert tips? Thousands of healthcare pros do—sign up for HCPLive's newsletter today!
